18F-FDG PET/CMR in cardiac sarcoidosis: A wild card in the deck?
- PMID: 33145740
- DOI: 10.1007/s12350-020-02427-3
18F-FDG PET/CMR in cardiac sarcoidosis: A wild card in the deck?
Comment on
-
Diagnostic utility of fusion 18F-fluorodeoxyglucose positron emission tomography/cardiac magnetic resonance imaging in cardiac sarcoidosis.J Nucl Cardiol. 2022 Apr;29(2):753-764. doi: 10.1007/s12350-020-02359-y. Epub 2020 Oct 1. J Nucl Cardiol. 2022. PMID: 33000410
References
-
- Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J. Sarcoidosis. Lancet 2014;383:1155-67. - DOI
-
- Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946-2013. Mayo Clin Proc 2016;91:183-8. - DOI
-
- Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol 2016;68:411-21. - DOI
-
- Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005;150:459-63. - DOI
-
- Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Hear Rhythm 2014;11:1304-23. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical